| Literature DB >> 19415577 |
Brock Ridenour1, Theda C Kontis.
Abstract
Injectable calcium hydroxylapatite (Radiesse) received FDA approval in 2006 for the correction of facial lipoatrophy and moderate to severe facial wrinkles. This product consists of microspheres of a synthetic bone suspended in a methylcellulose gel matrix. Because the product is thicker than the hyaluronic acids, it is used for the correction of moderate to severe wrinkles, such as deep nasolabial folds. It is also used "off-label" to treat multiple areas of the face, nose, and hands. Radiesse is injected into the subdermal plane, and correction lasts approximately 1 year after injection.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19415577 DOI: 10.1055/s-0029-1220649
Source DB: PubMed Journal: Facial Plast Surg ISSN: 0736-6825 Impact factor: 1.446